New England Capital Financial Advisors »

Sarepta Therapeutics shares owned by New England Capital Financial Advisors

Quarter-by-quarter ownership of Sarepta Therapeutics (SRPT) shares owned by New England Capital Financial Advisors from 13F filings

Historical chart of New England Capital Financial Advisors investment in Sarepta Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sarepta Therapeutics held by New England Capital Financial Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sarepta Therapeutics by New England Capital Financial Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $21k 1.1k 19.27
2025-06-30 $19k 1.1k 17.10
2025-03-31 $19k 300 63.82

More positions owned by New England Capital Financial Advisors

Capital Group Growth Etf Shs Creation Uni (CGGR)
American Centy Etf Tr Us Sml Cp Valu (AVUV)
Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Ssga Active Etf Tr Mult Ass Rlrtn (RLY)
Capital Grp Fixed Incm Etf T Core Plus Incm (CGCP)
Spdr Series Trust Prtflo S&p500 Gw (SPYG)
Spdr Series Trust Prtflo S&p500 Vl (SPYV)
Spdr Index Shs Fds Portfolio Devlpd (SPDW)
Capital Grp Fixed Incm Etf T Short Duration (CGSD)
Spdr Series Trust S&P 600 SMCP GRW (SLYG)
Capital Group Dividend Value Shs Creation Uni (CGDV)
Capital Grp Fixed Incm Etf T Municipal Income (CGMU)
Columbia Etf Tr Ii Em Core Ex Etf (XCEM)
Cohen & Steers Etf Trust Real Estate Acti (CSRE)
Morgan Stanley Etf Trust Eaton Vance Fltg (EVLN)

View all positions for New England Capital Financial Advisors

Top funds holding Sarepta Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Susquehanna International
Erste Asset Management GmbH
Renaissance Technologies
Two Sigma Investments
D. E. Shaw & Co
UBS Group
Standard Life Aberdeen
Two Sigma Advisers
First Trust Advisors
Citadel Advisors
Bnp Paribas Arbitrage, Snc
Connor, Clark & Lunn Investment Management

View all funds holding Sarepta Therapeutics